AdvaMed® Advancements: Q4 2025 Report
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
Tariffs
Stay up to date on tariff policies that impact your global operations. This section provides insights on trade developments, regulatory changes, and AdvaMed’s advocacy to minimize tariff burdens on medtech manufacturers and maintain global supply chain stability.
AdvaMed Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech
WASHINGTON—AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.
AdvaMed® Advancements: Q3 2025 Report
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to…
The Economic Impact of the Medical Technology Industry 2024
Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy
AdvaMed Responds to Commerce Department Section 232 National Security Investigation, Seeks Policies to Strengthen U.S. Position as Global Medtech Leader
WASHINGTON—AdvaMed, the medtech association, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.’s current level of medtech imports has national security implications. The…
AdvaMed Statement on Commerce Department Section 232 National Security Investigation
WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into…
Tariff-related Litigation Update – 9/12
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 9/5
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 8/22
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 8/15
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.